Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
about
The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple SclerosisA prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: the Dutch Multiple Sclerosis Study protocol.A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity.Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination.Income in Multiple Sclerosis Patients with Different Disease Phenotypes.The Swedish MS registry – clinical support tool and scientific resource.Beta-interferon exposure and onset of secondary progressive multiple sclerosis.Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countries.A changing treatment landscape for multiple sclerosis: challenges and opportunities.Can we measure long-term treatment effects in multiple sclerosis?Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?Defining secondary progressive multiple sclerosis.Treatment decisions in multiple sclerosis - insights from real-world observational studies.The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.Pediatric-onset multiple sclerosis in Egypt: a multi-center registry of 186 patients.Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis.Impact of Pilates Exercise in Multiple Sclerosis: A Randomized Controlled Trial.
P2860
Q31121073-02867E02-C713-4664-A793-52873DBF8E35Q35736039-D2BF68C5-2771-4C4D-89DB-F2E4D2352DBCQ35747637-770F8382-A810-4DB7-9510-B6FEE6BC8EF9Q35910495-7935EB0E-B730-42C5-919E-DBE8459F67A8Q36247525-74783AF6-DA0B-4843-AD13-03914534923FQ36311304-6B6F06D6-FED5-47E2-814C-E4A536973911Q37225075-412DEECB-1A98-4EAB-8D47-7A07A39FF358Q37424282-A17B7DEE-F0E2-4C28-BA27-BADBE4A47899Q38180166-C4F31C48-928C-4919-868E-510D35515FBDQ38298427-077153F1-886D-46EF-9037-43ADD05DAD22Q38375605-1C340E6B-49AD-4BB5-AAE2-DD932E5D78DAQ38677868-2C59DD17-8BE8-4688-B9BC-1A7D9062D6E9Q38777286-5CAA8B6C-D54F-43BB-8FD6-F327AD257B45Q38843046-97D0349D-2191-4039-A0D6-6AC597FB8298Q39022643-D96EA7AD-2744-4103-BD44-44F634075D92Q41355196-87C13704-EC1B-48E3-AA24-E976426549BFQ52674902-341D316C-D8C0-42AF-B244-5F664A745E22Q55129463-EF211661-F0D3-4EE1-BA74-D9B110518D85Q55262481-93C447C4-7482-40E5-98F8-C7FC28C48DEF
P2860
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Time to secondary progression ...... ration immunomodulating drugs.
@en
type
label
Time to secondary progression ...... ration immunomodulating drugs.
@en
prefLabel
Time to secondary progression ...... ration immunomodulating drugs.
@en
P2093
P2860
P50
P356
P1476
Time to secondary progression ...... eration immunomodulating drugs
@en
P2093
B Runmarker
H Tedeholm
L Stawiarz
O Andersen
P2860
P304
P356
10.1177/1352458512463764
P577
2012-11-01T00:00:00Z